Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11968945 | 0.88 | IGF1R (0.53) | HRH3ALDH1A1KMT2AIGF1RMEN1 | |
| SCHEMBL1460382 | 0.85 | DRD2 (0.53) | HRH3ALDH1A1KMT2AMEN1 | |
| SCHEMBL1460371 | 0.83 | HRH3 (0.53) | HRH3ALDH1A1SIGMAR1KMT2AIGF1R | |
| SCHEMBL1462399 | 0.81 | KDM4E (0.57) | ALDH1A1TP53HTTSIGMAR1KMT2A | |
| SCHEMBL1461382 | 0.81 | GMNN (0.55) | HRH3ALDH1A1TP53KMT2ASLC18A3 | |
| SCHEMBL1460271 | 0.80 | MEN1 (0.59) | ALDH1A1KMT2ASLC18A3MEN1 | |
| SCHEMBL1460278 | 0.79 | MEN1 (0.61) | KMT2ASLC18A3MEN1 | |
| SCHEMBL1460466 | 0.78 | GRIN1 (0.45) | HRH3KMT2ASLC18A3MEN1 | |
| SCHEMBL1461553 | 0.78 | TACR1 (0.47) | HRH3ALDH1A1TACR1KMT2AIGF1R | |
| SCHEMBL11968885 | 0.77 | ALDH1A1 (0.59) | HRH3ALDH1A1TP53MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | HRH3 270/4885ALDH1A1 796/4885TP53 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.